This Used-Car Rocket Just Got a Fancy New Coat of Paint

A used-car high-flyer is moving into the market’s main clubhouse after a jaw-dropping rally, tempting traders to forget how far it’s already run. If you’ve enjoyed the ride, and if you’re just arriving, buckle up. We believe this ride just kicked into high gear, and you’re going to want to be in the passenger seat.

This one indicator has quietly helped catch major moves long before they turned into headlines.

The trader behind it says it signaled multiple rallies and it’s firing again right now.

Missing this could mean missing the next setup as it forms.

Get the free indicator instantly on the next page.

Futures are drifting sideways to start the week, with Wall Street catching its breath after two winning laps and the S&P sitting just shy of record territory. The real show is later this week as the Fed steps on stage, with traders betting on a cut and just as eager to parse the dot plot and leadership tea leaves.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

IBM (NYSE: IBM) is reportedly circling an $11 billion deal for Confluent Inc (NASDAQ: CFLT), basically trying to buy the pipes that move all the real-time data other companies are obsessed with.

Think bank swipes, app clicks, and every other digital breadcrumb flowing through one giant stream. If Big Blue grabs that, it gets closer to where the cloud and AI money is actually moving.

The flip side is that IBM already promised the street it would be a software and AI growth story, and this would be another big swing to prove it. Big deals come with integration headaches, culture clashes, and the risk that you pay yesterday’s price for tomorrow’s slower growth. The stock has had a strong run this year, so expectations aren’t exactly cheap.

For you, the move is to watch how the market reacts once the terms are official. If investors treat it as a smart bolt-on and the stock only wiggles, that’s a quiet vote of confidence. If it spikes on day one, you don’t have to chase the first candle.

My Take For You: If you’re curious, think small size only and add later if the deal closes and execution looks sane. If you already own it, use any big pop to trim a little while everyone’s excited about synergies.

My Verdict: Solid long-term watch-list name, but treat an M&A headline as a chance to rebalance, not a reason to suddenly go all-in on grandpa tech.

Ocular Therapeutix Inc (NASDAQ: OCUL) just told investors it’s ready to march an eye drug, AXPAXLI, toward the FDA based on year-one Phase 3 data.

The company thinks the results are strong enough to ask regulators for a green light sooner instead of waiting around for extra seasons of the same show. The market loves that kind of confidence, which is why the stock’s been perking up.

Of course, this is biotech, not a Hallmark movie. The FDA can always ask for more data, more patients, more time. There’s also the risk that when the full readout arrives in 2026, it doesn’t look quite as shiny as everyone hoped.

Between now and then, you’re basically riding on expectations, leaks, and every rumor from conference hallways.

The upside if things go right is obvious. This becomes a real product, real revenue, and a pipeline that suddenly looks a lot more legit. The downside is a classic biotech rug-pull if the data or the dialogue with regulators goes sideways.

My Take For You: If you’re new, treat this as a speculative side quest with a small position only, and be honest about whether you can handle drama around data dates. If you’re already in, consider peeling off some profits on big green days and letting the rest ride into the 2026 readout.

My Verdict: High-beta story stock. Fun for a modest slice of a portfolio that can stomach clinical plot twists, but not the place to park rent money or your emergency fund.

Every market cycle produces a handful of companies that outperform by a wide margin.

Recent screening results reveal 5 promising stocks with rare signals that historically show up before major upside momentum.

The latest report explains why these names could be positioned for significant gains in the coming year.

Previous reports revealed stocks that later climbed +175 percent, +498 percent, and +673 percent.¹

Download the Free 5 Stocks Report Before Midnight.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Carvana Co (NYSE: CVNA) is getting the golden ticket into the S&P 500, which is how you go from might go bankrupt to “hi, I’m in your index fund” in a couple of years. The stock has ripped so hard off its lows that it now sits above some old-school automakers, which is wild when you remember it just sells used cars on the internet, not flying taxis.

Index inclusion is like getting added to the cool-kids group chat: big funds are forced to buy, short sellers sweat a bit, and the chart usually looks like it slammed an energy drink.

But what made this possible, the tight cost control, better margins, and a rebound in demand, now has to keep working in real time, not just on slides. Any stumble from here gets judged against a much fancier share price.

So you’ve basically got a Cinderella story that already went through the montage and is now playing in the fourth quarter. You can absolutely trade the momentum, just don’t confuse it with a sleepy, stable car stock.

My Take For You: If you’re tempted, think tight exit rules, as this is more roller coaster than commuter train. If you’ve been in since the dark days, congrats. Now’s a smart time to lock in some gains while the index crowd is still doing the buying for you.

My Verdict: Great for thrill-seekers and momentum traders, watch-list only for everyone else. Enjoy the S&P victory lap, but don’t assume 8,000% gains are a repeatable part of the business model.

Traders are crowding in ahead of Monday’s eczema drug update, treating this like a biotech scratch ticket with a better story than usual.

The early data looked clean, so hope is high that this pill can hang with the big-name injections.

This cement-and-asphalt giant just got the “welcome to the S&P 500” email and fired up a fresh buyback, which is basically Wall Street catnip.

It’s the kind of boring-on-paper business that quietly benefits when index funds and long-only managers are forced to pile in.

After a big AI-fueled run, this chip name is catching its breath while everyone argues whether it’s the next backbone of data centers or just priced like it already won.

Record results and a flashy photonics deal are great, but even good stories need pauses.

A select group of stocks has risen to the top of this month’s short-term rankings.

Each one passed a data-driven screen for near-term growth potential.

The complete list is now available for free viewing.

Discover which stocks could be poised for strong performance this month.

See the Free 7 Best Stocks Report Now

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.